Vous avez cherché: hematopoetskih (Croate - Anglais)

u bolesnika nakon alogene transplantacije hematopoetskih matičnih stanica
hypogammaglobulinaemia (<4 g/l) in patients after allogeneic haematopoietic stem cell transplantation

hipogamaglobulinemija u bolesnika nakon alogene transplantacije hematopoetskih matičnih stanica
hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation

hipogamaglobulinemiji u bolesnika nakon alogene transplantacije hematopoetskih matičnih stanica.
hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (hsct).

istodobna primjena hematopoetskih čimbenika rasta i jakavija nije do sada proučavana.
the concurrent use of haematopoietic growth factors and jakavi has not been studied.

ne postoji poznati protulijek za busilvex osim presađivanja hematopoetskih progenitorskih stanica.
there is no known antidote to busilvex other than haematopoietic progenitor cell transplantation.

prva je doza primijenjena tri do šest mjeseci nakon presađivanja hematopoetskih matičnih stanica.
the first dose was administered at 3 to 6 months after hsct.

ovaj pripremni lijek primit ćete prije presađivanja koštane srži ili hematopoetskih progenitorskih stanica.
you will receive this preparative medicine before receiving a transplant of either bone marrow or haematopoietic progenitor cell.

istodobna primjena citoreduktivnih terapija ili hematopoetskih čimbenika rasta s jakavijem nije do sada proučavana.
the concomitant use of cytoreductive therapies or haematopoietic growth factors with jakavi has not been studied.

doziranje kod bolesnika s prethodno neliječenim multiplim mijelomom za koje transplantacija hematopoetskih matičnih stanica nije prikladna
posology for previously untreated multiple myeloma patients not eligible for haematopoietic stem cell transplantation

busulfan se koristi prije presađivanja za uništavanje abnormalnih stanica i postojećih hematopoetskih progenitorskih stanica bolesnika.
busulfan is used before transplantation to destroy abnormal cells and the patient’s existing haematopoietic progenitor cells.

anamneze transplantacije vitalnih organa ili transplantacije hematopoetskih matičnih stanica/ koštane srži ili transplantacije bubrega.
a history of major organ transplant or hematopoietic stem /cell /marrow transplant or renal transplant.

odraslih osobakoje nisu prethodno liječene i za koje nije prikladna kemoterapija u visokim dozama s transplantacijom hematopoetskih matičnih stanica.
previously untreated adults who cannot have high-dose chemotherapy with a blood stem-cell transplant.

bolesnici profilaktički liječeni mikafunginom bili su oni na transplantaciji matičnih hematopoetskih stanica i u kojih je postojao visoki rizik od gljivičnih infekcija.
patients treated prophylactically with micafungin were those undergoing haematopoetic stem cell transplantation (hsct) who were at high risk for fungal infections.

kao i kod drugih hematopoetskih čimbenika rasta, g-csf in vitro iskazuje stimulirajuće djelovanje na ljudske endotelne stanice.
as with other haematopoietic growth factors, g-csf has shown in vitro stimulating properties on human endothelial cells.

defitelio se izdaje samo na liječnički recept te ga mora propisivati i primjenjivati liječnik specijalist s iskustvom u upravljanju komplikacijama povezanih s transplantacijom hematopoetskih matičnih stanica.
defitelio can only be obtained with a prescription and must be prescribed and given by a doctor experienced in the management of complications of haematopoietic stem cell transplantation.

busilvex u kombinaciji s kiklofosfamidom ili melpfalanom ispitan je u bolesnika, uglavnom s rakom krvi, kojima je bilo potrebno presađivanje hematopoetskih progenitorskih stanica.
busilvex in combination with cyclophosphamide or melphalan has been studied in patients, mainly with blood cancer, who needed transplantation of haematopoietic progenitor cells.

bortezomib accord je indiciran u kombinaciji s deksametazonom ili s deksametazonom i talidomidom kao uvodno liječenje odraslih bolesnika s prethodno neliječenim multiplim mijelomom za koje je prikladna kemoterapija u visokim dozama s transplantacijom hematopoetskih matičnih stanica.
bortezomib accord in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

bortezomib accord je indiciran u kombinaciji s rituksimabom, ciklofosfamidom, doksorubicinom i prednizonom za liječenje odraslih bolesnika s prethodno neliječenim limfomom plaštenih stanica za koje nije prikladna transplantacija hematopoetskih matičnih stanica.
bortezomib accord in combination with rituximab, cyclophosp hamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

bortezomib accord se također koristi za liječenje limfoma plaštenih stanica, drugog raka krvi, u odraslih osoba koje nisu primile terapiju, a za koje nije prikladna transplantacija hematopoetskih matičnih stanica.
bortezomib accord is also used to treat mantle cell lymphoma, another blood cancer, in untreated adults who cannot have blood stem-cell transplantation.

busilvex koji slijedi nakon fludarabina (fb) indiciran je kao terapija kondicioniranja prije presađivanja hematopoetskih progenitorskih stanica u odraslih bolesnika koji su kandidati za protokol kondicioniranja smanjenog intenziteta.
busilvex following fludarabine (fb) is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation (hpct) in adult patients who are candidates for a reduced-intensity conditioning (ric) regimen.